hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 14:50:03 - browse：6812

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Digital health funding stays low as a new reality sets in

explore

Wikipedia

WSS

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Sutter Health’s antitrust win overturned by appeals court

A Greenpeace activist is fined for crash

STAT wants to know your pick for a great summer read or listen

Finland to offer bird flu vaccine to select groups of people, a possible global first

Take antibiotics after sex, CDC recommends for certain risk groups

focus

hotspot

knowledge

Heart attack and stroke risk calculators need revising

Sickle cell gene therapy cures need to be accessible in Africa

Walensky prepares to leave CDC — and Congress — behind

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Virginia high school admissions case could be legal follow

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

23andMe had bad news about my health. I wish a person had delivered it

Illumina board agrees to spin off Grail, as divestment plans proceed

Activists slam private health insurers over coverage restrictions

Inflation cooled significantly in June, bringing price hikes close to normal levels

Wikipedia

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

EU fines Illumina $475 million over Grail acquisition

Structure Therapeutics oral GLP

Congress needs to close a vaccine

Sickle cell gene therapy cures need to be accessible in Africa

China sends large group of warplanes, navy ships towards Taiwan in forceful display

explore

Wikipedia

hotspot

explore